The known epileptics in the practice were identified from the practice morbidity register and their records reviewed. They were then divided into (1) patients who had received anticonvulsants or had suffered fits during the preceding two years, and (2) patients who had neither received anticonvulsants nor been known to have had fits during that time. All group 1 patients other than those under hospital surveillance were invited to attend for a clinical assessment, which included haematological investigations and measurement of serum anticonvulsant concentrations. Records of diagnosis and management were then reviewed at a meeting between the patient's general practitioner and a neurologist (PF).
Out of 64 patients recorded as epileptics 12 had died or left the practice at the time of the review. The remaining 52 gave a prevalence rate of 7 6/ 1000, compared with 3-0-6-2/1000 reported by others. (7) 1 (4) four of the 21 patients reviewed in group 1 had had a fit in the preceding year, and a further four had had fits within the preceding two years. Thirteen had had no fits during this period. Out of the four attending hospital the fits in three were very difficult to control, and the fourth, an 85-year-old man, had attended for 30 years for his medication and refused to discontinue this practice. The anatomical interrelationship between dopaminergic and gammaaminobutyric acid (GABA) neurons and evidence for functional antagonism between these systems have led investigators to suggest that conditions thought to be related to dopaminergic hyperfunction such as schizophrenia and tardive dyskinesia might be beneficially affected by GABA facilitation.' Trials of putative GABA agonists such as baclofen' and sodium valproate,4 and of the specific GABA agonist muscimol5 represent attempts to use this approach in these conditions. The results of such studies have, however, often been contradictory. We report here an extrapyramidal syndrome emerging during a trial in which the effect of sodium valproate on schizophrenic psychopathology was being assessed.
Case report
A 52-year-old man with a history of chronic schizophrenia from early adult life was treated with sodium valproate alone. He had been admitted to hospital several times before, when standard neuroleptic agents had diminished but never completely abolished his symptoms. By the fourth day of treatment with sodium valproate 1 g/day the patient developed a pronounced bilateral, low amplitude Parkinsonian-like tremor of the arms.
Associated with this tremor was a circumoral tremor of the same frequency.
Cogwheel rigidity of the arms was demonstrable only after reinforcement. The intensity of these signs increased with increasing dosage. At 1-5 g/day he was given 2 mg benztropine intravenously with no clinical effect. At
